Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 20-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-12?-hydroxydammar-24-en-3?-yl 2-O-?-D-glucopyranosyl-?-D-glucopyranoside
- Correlated keywords
- 12770-?17-?1 52286-?61-?0 87700-?07-?0 212055-?66-?8 393829-?67-?9 natural products neurosciences inflammation obesity apoptosis ginesosides ginseng plants genus panax protopanaxadiol species P. quinquefolium in vitro vivo neuroprotective anti-inflammatory anti inflammatory antiinflammatory anti-obesity obesity antiobesity steroids Rb1 arasaponin E1 gynosaponin C gypenoside III NSCs 310103 NSC-310103 NSC310103 notoginsenoside panaxoside sanchinoside glycosides triterpenes squalene p-38 A?-40 NF?B
- Product Overview:
Ginsenoside Rb1 is a triterpene saponin that has been found in P. ginseng and has diverse biological activities.{24876,24875,67161,67162,67163} It decreases apoptosis and increases in protein kinase A (PKA), PKC, caspase-3, and caspase-9 levels induced by isoproterenol (Item No. 15592) in H9c2 rat cardiomyocytes when used at a concentration of 100 µM.{24876} Ginsenoside Rb1 (1 µM) inhibits glucose-induced cytotoxicity and production of reactive oxygen species (ROS) in primary rat hippocampal neurons.{24875} It inhibits LPS-induced activation of IL-1 receptor-associated kinase 1 (IRAK1), I???, NF-?B, as well as the MAP kinases ERK, JNK, and p38, in mouse peritoneal lavage fluid when used at a concentration of 100 µM.{67162} Ginsenoside Rb1 (10 mg/kg for 30 days) increases hippocampus nestin and glial fibrillary acidic protein (GFAP) levels, markers of neural stem cells and astrocytes respectively, in a rat model of Alzheimer’s disease induced by amyloid-? (1-40) (A?40).{67161} It decreases high-fat diet-induced increases in liver weight, hepatic triglyceride accumulation, serum fasting glucose levels, and serum LDL levels in a mouse model of obesity when administered at a dose of 200 mg/kg per day.{67163}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.